INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Jan 12, 2021 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Bona fide gift | 82,108 | -- | 82,108 |
| Dec 11, 2019 |
Director, President and CSO
|
Director, President and CSO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 81,278 | -- | 81,278 |
| Mar 09, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 78,376 | $476.42 | 635,614 |
| Dec 12, 2019 |
Director, President and CSO
|
Director, President and CSO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 77,767 | $377.16 | 444,109 |
| Dec 13, 2018 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 76,863 | $377.31 | 73,137 |
| Aug 05, 2019 |
Director, President and CSO
|
Director, President and CSO | Form 4 | Bona fide gift | 75,036 | -- | -- |
| Aug 05, 2019 |
Director, President and CSO
|
Director, President and CSO | Form 4 | Bona fide gift | 75,036 | -- | 328,352 |
| Dec 16, 2008 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 73,009 | $7.41 | 636,103 |
| Dec 16, 2008 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 73,009 | -- | -- |
| Jan 05, 2005 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | 70,000 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.